Press releases
- Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs
- Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists
- Incyte to Report First Quarter Financial Results
- Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia
- Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis Suppurativa
- Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis
- New Data from Incyte’s Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting
- Incyte Launches The Unseen Journey to Elevate the Hidden Impact of Myeloproliferative Neoplasms (MPNs) on Patients’ Lives through Generative AI
- Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease
More ▼
Key statistics
As of last trade INCYTE CORP DRN (I1NC34:SAO) traded at 135.90, 0.00% above its 52-week low of 135.90, set on Apr 22, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 135.90 |
---|---|
High | 135.90 |
Low | 135.90 |
Bid | 134.40 |
Offer | 135.52 |
Previous close | 135.90 |
Average volume | 10.00 |
---|---|
Shares outstanding | -- |
Free float | -- |
P/E (TTM) | -- |
Market cap | -- |
EPS (TTM) | -- |
Data delayed at least 15 minutes, as of May 02 2024 14:42 BST.
More ▼